B domain containing Tenascin-C: A new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder?

Clinica Chimica Acta

Volumn 412, Issue 21-22, 2011, Pages 1931-1936

  Gecks, T ^a   Junker, K ^a   Franz, M ^a   Richter, P ^a   Walther, M ^a   Voigt, A ^a   Neri, D ^b   Kosmehl, H ^c   Wunderlich, H ^a   Kiehntopf, M ^a   Berndt, A ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b ETH ZURICH   (Switzerland)

^c HELIOS KLINIKUM ERFURT   (Germany)

Author keywords

ELISA; Invasion; Splicing domains; Tumour surveillance; Urinary Tenascin C; Urothelial carcinoma of the urinary bladder

Indexed keywords

TENASCIN; TUMOR MARKER;

ADULT; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; REFERENCE VALUE; TRANSITIONAL CELL CARCINOMA; URINE LEVEL;

CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; TENASCIN; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 80051678162     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.06.038     Document Type: Article

References (33)

1. Raghavan D., Huben R. Management of bladder cancer. Curr Probl Cancer 1995, 19:1-64.
2. Kraywinkel K., Husmann G., Kaatsch P., Katalinic A., Bertz J., Haberland J. Cancer in Germany 2005/2006 incidence and trends 2010, Robert Koch Institute and the Association of Population-based Cancer Registries in Germany, Berlin. seventh edition.
3. Ioachim E., Michael M., Stavropoulos N.E., Kitsiou E., Salmas M., Malamou-Mitsi V. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int 2005, 95:655-659.
4. Richter P., Junker K., Franz M., et al. IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC). J Cancer Res Clin Oncol 2008, 134:1059-1065.
5. Erickson H.P., Inglesias J.L. A six-armed oligomer isolated from cell surface fibronectin preparations. Nature 1984, 311:267-269.
6. Bourdon M.A., Wikstrand C.J., Furthmayr H., Matthews T.J., Bigner D.D. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 1983, 43:2796-2805.
7. Pilz A., Moseley H., Peters J., Abbott C. Comparative mapping of mouse chromosome 4 and human chromosome 9: Lv, Orm, and Hxb are closely linked on mouse chromosome 4. Mamm Genome 1992, 3:247-249.
8. Hancox R.A., Allen M.D., Holliday D.L., et al. Tumour-associated Tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 2009, 11:R24.
9. Lyons A.J., Jones J. Cell adhesion molecules, the extracellular matrix and oral squamous carcinoma. Int J Oral Maxillofac Surg 2007, 36:671-679.
10. Parekh K., Ramachandran S., Cooper J., Bigner D., Patterson A., Mohanakumar T. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer 2005, 47:17-29.
11. Katenkamp K., Berndt A., Hindermann W., et al. mRNA expression and protein distribution of the unspliced Tenascin-C isoform in prostatic adenocarcinoma. J Pathol 2004, 203:771-779.
12. Berndt A., Anger K., Richter P., et al. Differential expression of Tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. J Cancer Res Clin Oncol 2006, 132:537-546.
13. Brunner A., Mayerl C., Tzankov A., et al. Prognostic significance of Tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol 2004, 57:927-931.
14. Sato A., Aonuma K., Imanaka-Yoshida K., et al. Serum Tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 2006, 47:2319-2325.
15. Franz M., Berndt A., Altendorf-Hofmann A., et al. Serum levels of large Tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 2009, 11:1057-1062.
16. Richter P., Tost M., Franz M., et al. B and C domain containing Tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?. J Cancer Res Clin Oncol 2009, 135:1351-1358.
17. Eble J.N., Sauter G., Epstein J.E., Sesterhenn I.A. World Health Organization classification of tumours, pathology and genetics of male genital organs 2004, IARC Press, Lyon.
18. Tsunoda T., Inada H., Kalembeyi I., et al. Involvement of large Tenascin-C splice variants in breast cancer progression. Am J Pathol 2003, 162:1857-1867.
19. Silacci M., Brack S.S., Späth N., et al. Human monoclonal antibodies to domain C of Tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 2006, 19:471-478.
20. Brack S.S., Silacci M., Birchler M., Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of Tenascin-C. Clin Cancer Res 2006, 12:3200-3208.
21. Pedretti M., Soltermann A., Arni S., Weder W., Neri D., Hillinger S. Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer 2009, 64:28-33.
22. Berndt A., Köllner R., Richter P., et al. A comparative analysis of oncofetal fibronectin and Tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochem Cell Biol 2010, 133:467-475.
23. Sullivan P.S., Chan J.B., Levin M.R., Rao J. Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res 2010, 2:412-440.
24. Keesee S.K., Briggman J.V., Thill G., Wu Y.J. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr 1996, 6:189-214.
25. Pirtskalaishvili G., Konety B.R., Getzenberg R.H. Update on urine-based markers for bladder cancer: how sensitive and specific are the new noninvasive tests?. Postgrad Med 1999, 106(85-6):91-94.
26. Ramakumar S., Bhuiyan J., Besse J.A., et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999, 161:388-394.
27. Tsihlias J., Grossman H.B. The utility of fibrin/fibrinogen degradation products in superficial bladder cancer. Urol Clin North Am 2000, 27:39-46.
28. Passerotti C.C., Bonfim A., Martins J.R., et al. Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder. Eur Urol 2006, 49:71-75.
29. Guttery D.S., Shaw J.A., Lloyd K., Pringle J.H., Walker R.A. Expression of Tenascin-C and its isoforms in the breast. Cancer Metastasis Rev 2010, 29:595-606.
30. Sherief M.H., Low S.H., Miura M., Kudo N., Novick A.C., Weimbs T. Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay. J Urol 2003, 169:1530-1534.
31. Burchardt E.R., Hein R., Bosserhoff A.K. Laminin, hyaluronan, Tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clin Exp Dermatol 2003, 28(5):515-520.
32. Ishiwata T., Takahashi K., Shimanuki Y., et al. Serum Tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res 2005, 25:489-495.
33. Terasaki F., Okamoto H., Onishi K., et al. Higher serum Tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 2007, 71:327-330.